Industry Overview

Fertility testing devices market was valued at $2.7 billion in 2025 and is projected to reach $5.6 billion by 2035, growing at a CAGR of 7.7% during the forecast Period (2026-2035). The market growth is driven by rising delayed pregnancies, increased infertility awareness, and tech advances like AI wearables and home sperm tests, making tracking easier. Key factors boosting growth include women delaying family for careers, rising PCOS cases, easy e-commerce access, and emerging male testing, though high costs and regulatory hurdles pose challenges. North America & Europe lead, but Asia-Pacific shows high growth owing to rising awareness.

Market Dynamics

Rising Infertility Prevalence and Delayed Parenthood

Globally, infertility rates are increasing due to lifestyle changes, stress, obesity, smoking, environmental exposure, and delayed family planning. Couples are choosing to conceive later in life, which heightens the need for early and regular fertility assessment. This demographic shift has made fertility testing devices such as ovulation prediction kits, hormone-based tests, and semen analysis tools an essential first step in reproductive planning. Growing awareness about fertility health among both women and men is encouraging proactive monitoring, significantly driving demand for easy-to-use, non-invasive, and affordable testing solutions.

Technological Advancements and Shift Toward Home-Based Diagnostics

Continuous innovation in fertility testing technologies is a major growth driver. The market is witnessing a transition from conventional strip-based tests to digital fertility monitors, smartphone-connected devices, and AI-enabled hormone tracking systems. These advanced devices offer higher accuracy, real-time data interpretation, and personalized insights, improving user confidence and outcomes. The convenience, privacy, and cost-effectiveness of home-based fertility testing devices are accelerating adoption, especially among tech-savvy consumers and those seeking alternatives to frequent clinical visits.

Expansion of E-Commerce, DTC Models, And Fertility-Focused Healthcare Ecosystems

The rapid growth of e-commerce platforms and direct-to-consumer (DTC) healthcare models has significantly improved access to fertility testing devices worldwide. Online pharmacies, brand-owned websites, and subscription-based models enable discreet purchasing and repeat usage of consumables such as test strips and cartridges. Additionally, partnerships between fertility device manufacturers, telehealth providers, and fertility clinics are strengthening integrated care pathways from home testing to professional consultation thereby expanding market penetration and long-term customer engagement across developed and emerging markets.

Market Segmentation

• Based on the product type, the market is segmented into ovulation prediction kits, fertility monitors, and male fertility testing products.
• Based on the mode of purchase, the market is segmented into over?the?counter (OTC), and prescription?
• Based on the end-user, the market is segmented into hospitals and fertility clinics, and home care setting.

Ovulation Prediction Kits Segment to Grow at a Considerable Market Share

Ovulation prediction kits (OPKs) represent the largest and leading segment in the Global Fertility Testing Devices Market, driven primarily by their widespread adoption in home care settings and strong availability through over-the-counter (OTC) channels. Within this category, urine-based ovulation kits dominate due to their high accuracy in detecting luteinizing hormone (LH) surges, affordability, ease of use, and rapid results, making them the preferred first-line fertility assessment tool for women trying to conceive. The growing awareness of reproductive health, increasing incidence of delayed pregnancies, and rising preference for non-invasive, self-administered fertility testing solutions have significantly boosted demand for OPKs compared to fertility monitors and male fertility testing products. Additionally, strong retail penetration, e-commerce growth, and minimal regulatory barriers for OTC products further reinforce the leadership of ovulation prediction kits, positioning this segment as the largest contributor to overall market revenue and growth globally.

Home Care Setting: A Key Segment in Market Growth

The home care setting represents the single most influential and fastest-growing segment in the global fertility testing devices market, driven by a strong shift toward self-managed and preventive reproductive health. Increasing awareness of fertility planning among women and couples, combined with delayed parenthood trends, has significantly boosted demand for convenient, private, and easy-to-use testing solutions that can be used at home. Home-based fertility testing devices such as ovulation prediction kits, hormone monitoring strips, and digital fertility trackers offer advantages including affordability, anonymity, and rapid results, making them highly attractive compared to clinic-based testing. The expansion of over-the-counter (OTC) availability further supports this segment, enabling consumers to purchase devices without medical consultations. Technological advancements, including smartphone connectivity, AI-based cycle tracking, and app-integrated hormone analysis, have improved accuracy and user engagement, strengthening consumer confidence in home testing.

Additionally, growing female workforce participation and busy lifestyles have increased the preference for at-home diagnostics that reduce time and cost burdens associated with hospital visits. In emerging economies, rising disposable income and expanding e-commerce platforms have improved access to home fertility testing products, accelerating adoption. Post-pandemic behavioral changes emphasizing remote and self-care diagnostics have also had a lasting positive impact. As a result, the home care setting is expected to remain the primary growth engine of the fertility testing devices market over the forecast period, outpacing hospital and clinic-based usage.

Regional Outlook

The global fertility testing devices market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global fertility testing devices market, accounting for the largest revenue share globally. This leadership is primarily driven by high awareness of fertility health, a strong culture of proactive reproductive planning, and widespread acceptance of at-home diagnostic testing. The US has a high prevalence of delayed parenthood, with many individuals choosing to conceive later in life due to career and lifestyle priorities, which significantly increases demand for ovulation prediction kits, digital fertility monitors, hormone-based tests, and at-home semen analysis devices. In addition, the country benefits from a well-established healthcare infrastructure, strong purchasing power, and extensive insurance and employer-supported fertility benefits that indirectly encourage fertility testing adoption.

The presence of leading fertility testing device manufacturers and brands such as Swiss Precision Diagnostics (Clearblue), Church & Dwight (First Response), Procter & Gamble, and several digital fertility startups further strengthens market dominance through continuous product innovation and aggressive direct-to-consumer marketing. Moreover, the rapid expansion of e-commerce, subscription-based testing models, and telehealth fertility platforms in the US  has improved product accessibility and consumer engagement. Regulatory clarity for over-the-counter diagnostic devices and high penetration of digital health technologies also support faster commercialization and adoption of advanced fertility testing solutions, enabling the United States to maintain a commanding share of the global fertility testing devices market.

Market Players Outlook

The major companies operating in the global fertility testing devices market include Abbott Laboratories, Church & Dwight Co., Inc., Prestige Consumer Healthcare Inc., Swiss Precision Diagnostics (SPD) GmbH, Quidel Corp., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In December 2025, INVO Fertility signed a definitive purchase agreement to acquire Family Beginnings, P.C., a fertility clinic in Indiana. This agreement follows INVO's announcement on November 27, 2025, and represents a step towards expanding its network of fertility care centers in the U.S. Family Beginnings reported revenues of approximately $1.2 million and a net income of about $0.2 million over the past year.
• In August 2023, Fertilly, launched Europe’s first At-Home Fertility Test Kits utilizing CE-IVD registered Mitra microsampling devices with VAMS technology. These medically certified kits allow individuals to collect dried blood samples at home via a quick finger-stick, which are then mailed to a lab for analysis. The Mitra devices ensure high-quality samples, minimizing the risk of inaccurate lab results. The test measures anti-Müllerian hormone (AMH) levels, indicating ovarian reserve, and provides women with personalized reports detailing their fertility status. Higher AMH levels correlate with better chances of natural conception or successful fertility treatments.
• In July 2023, Quest Diagnostics and Proov collaborated to offer the Proov Confirm PdG home fertility test kit through questhealth.com. It is the first FDA-cleared home test for measuring progesterone metabolite (PdG) to confirm ovulation. This test, aimed at women looking to start or expand their families, assesses hormone levels during the implantation window. Alongside this, Quest's offerings include a range of fertility assessment tests such as the Ovarian Reserve Assessment Marker Test, hCG Pregnancy Test, Pre-Pregnancy Test Panel, and Testosterone Test for men.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global fertility testing devices market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.